MEIS1 and its potential as a cancer therapeutic target (Review)

Abstract

Meis homeobox 1 (Meis1) was initially discovered in 1995 as a factor involved in leukemia in an animal model. Subsequently, 2 years later, MEIS1, the human homolog, was cloned in the liver and cerebellum, and was found to be highly expressed in myeloid leukemia cells. The MEIS1 gene, located on chromosome 2p14, encodes a 390-amino acid protein with six domains. The expression of homeobox protein MEIS1 is affected by cell type, age and environmental conditions, as well as the pathological state. Certain types of modifications of MEIS1 and its protein interaction with homeobox or pre-B-cell leukemia homeobox proteins have been described. As a transcription factor, MEIS1 protein is involved in cell proliferation in leukemia and some solid tumors. The present review article discusses the molecular biology, modifications, protein-protein interactions, as well as the role of MEIS1 in cell proliferation of cancer cells and MEIS1 inhibitors. It is suggested by the available literature MEIS1 has potential to become a cancer therapeutic target. Contents 1. Introduction 2. Molecular biology of MEIS1 3. Modification 4. Protein-protein interactions 5. Role of MEIS1 in the proliferation of cancer cells 6. MEIS1 inhibitors 7. conclusions and future perspectives

MEIS1 in Hematopoiesis and Cancer. How MEIS1-PBX Interaction Can Be Used in Therapy

“…Notably, most of these drugs downregulate the levels of MEIS1. More recently, Yao and colleagues [120] reported the current status on the development of MEIS1 inhibitors as therapeutic agents. 9.1.1.…”

Novel low‐grade renal spindle cell neoplasm with HEY1::NCOA2 fusion that is distinct from mesenchymal chondrosarcoma

“…24 MEIS1 is similar to HEY1 in that it binds directly to DNA to influence transcription, although unlike HEY1, it partners with homeobox proteins. 25 In addition, MEIS1::NCOA2 cases have more primitive histology with compact cells and without the degree of stromal differentiation seen in this case. This case study is the first reported primary renal spindle cell neoplasm with a HEY1::NCOA2 fusion that is distinct from mesenchymal chondrosarcoma and does not fit criteria for any other known diagnosis.…”

“…Rare NCOA2 fusions have been reported in primary renal spindle cell sarcomas, specifically MEIS1::NCOA2 fusion primitive spindle cell sarcoma involving the genitourinary and gynecological tracts 24 . MEIS1 is similar to HEY1 in that it binds directly to DNA to influence transcription, although unlike HEY1 , it partners with homeobox proteins 25 . In addition, MEIS1::NCOA2 cases have more primitive histology with compact cells and without the degree of stromal differentiation seen in this case.…”

A Systematic Pan-Cancer Analysis of MEIS1 in Human Tumors as Prognostic Biomarker and Immunotherapy Target

“…As a transcription factor, MEIS1 drives cell growth [ 19 ], dysregulated MEIS1 expression contributes to tumorigenesis in multiple tumor types [ 12 , 20 , 21 , 22 , 23 ]. Due to its role in cancer cell proliferation, MEIS1 can become a molecular biomarker for cancer diagnosis and even a target for cancer therapy [ 24 ]. However, the expression levels of MEIS1 in various tumors are different [ 10 , 24 ].…”